%0 Journal Article %1 chevallier_safety_2009 %A Chevallier, Bertrand %A Vesikari, Timo %A Brzostek, Jerzy %A Knuf, Markus %A Bermal, Nancy %A Aristegui, Javier %A Borys, Dorota %A Cleerbout, Jan %A Lommel, Patricia %A Schuerman, Lode %D 2009 %J The Pediatric Infectious Disease Journal %K Bacterial C, Carrier Combined, Conjugate Controlled D, Female, Humans, Immunization Immunization, Immunoglobulin Infant, Lipoproteins, Male, Meningococcal Neisseria Outcome, Pneumococcal Programs, Proteins, Randomized Schedule, Secondary, Serogroup Topic, Treatment Trials Vaccination, Vaccines, as meningitidis, %N 4 Suppl %P S109--118 %R 10.1097/INF.0b013e318199f62d %T Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines %U http://www.ncbi.nlm.nih.gov/pubmed/19325447 %V 28 %X BACKGROUND: Licensed pneumococcal conjugate vaccine (7vCRM) is usually coadministered with combination vaccines in pediatric immunization programs. Reactogenicity and safety after primary and booster vaccination with a novel 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) in comparison with 7vCRM, both coadministered with commonly used pediatric vaccines, was evaluated in 5 clinical studies. METHODS: Five randomized, controlled studies in which PHiD-CV or licensed 7vCRM vaccines coadministered with various DTPa-based combination vaccines, Neisseria meningitidis serogroup C conjugate vaccines and DTPw-HBV/Hib were conducted. Local and general symptoms were solicited for 4 days after each vaccine dose, using diary cards. All adverse events were recorded for 31 days after each dose and serious adverse events throughout the entire study periods. RESULTS: A total of 4004 subjects contributed to the safety data analyzed in this review. Fever \textgreateror=38.0 degrees C (rectal temperature) was reported after about one-third of primary or booster vaccine doses coadministered with DTPa-based vaccines and after approximately 60\% of primary doses with DTPw coadministration in both PHiD-CV and 7vCRM groups. Fever \textgreater40.0 degrees C was reported after \textlessor=1.1\% of PHiD-CV doses and \textlessor=2.2\% of 7vCRM doses. The incidences and intensity of general reactions were generally within the same ranges in the PHiD-CV and 7vCRM groups. Drowsiness and irritability in the study with MenC-conjugates coadministration and irritability and loss of appetite in the study with DTPw-combined vaccines coadministration tended to be slightly higher in PHiD-CV groups. No such trend was observed for solicited general symptoms with grade 3 intensity. CONCLUSIONS: The safety and reactogenicity profiles of PHiD-CV and 7vCRM were within the same range when administered for primary and booster vaccination in coadministration with other routinely used pediatric vaccines.

@article{chevallier_safety_2009, abstract = {{BACKGROUND:} Licensed pneumococcal conjugate vaccine {(7vCRM)} is usually coadministered with combination vaccines in pediatric immunization programs. Reactogenicity and safety after primary and booster vaccination with a novel 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine {(PHiD-CV)} in comparison with {7vCRM,} both coadministered with commonly used pediatric vaccines, was evaluated in 5 clinical studies. {METHODS:} Five randomized, controlled studies in which {PHiD-CV} or licensed {7vCRM} vaccines coadministered with various {DTPa-based} combination vaccines, Neisseria meningitidis serogroup C conjugate vaccines and {DTPw-HBV/Hib} were conducted. Local and general symptoms were solicited for 4 days after each vaccine dose, using diary cards. All adverse events were recorded for 31 days after each dose and serious adverse events throughout the entire study periods. {RESULTS:} A total of 4004 subjects contributed to the safety data analyzed in this review. Fever {\textgreater}or=38.0 degrees C (rectal temperature) was reported after about one-third of primary or booster vaccine doses coadministered with {DTPa-based} vaccines and after approximately 60\% of primary doses with {DTPw} coadministration in both {PHiD-CV} and {7vCRM} groups. Fever {\textgreater}40.0 degrees C was reported after {\textless}or=1.1\% of {PHiD-CV} doses and {\textless}or=2.2\% of {7vCRM} doses. The incidences and intensity of general reactions were generally within the same ranges in the {PHiD-CV} and {7vCRM} groups. Drowsiness and irritability in the study with {MenC-conjugates} coadministration and irritability and loss of appetite in the study with {DTPw-combined} vaccines coadministration tended to be slightly higher in {PHiD-CV} groups. No such trend was observed for solicited general symptoms with grade 3 intensity. {CONCLUSIONS:} The safety and reactogenicity profiles of {PHiD-CV} and {7vCRM} were within the same range when administered for primary and booster vaccination in coadministration with other routinely used pediatric vaccines.}, added-at = {2011-03-11T10:05:34.000+0100}, author = {Chevallier, Bertrand and Vesikari, Timo and Brzostek, Jerzy and Knuf, Markus and Bermal, Nancy and Aristegui, Javier and Borys, Dorota and Cleerbout, Jan and Lommel, Patricia and Schuerman, Lode}, biburl = {https://www.bibsonomy.org/bibtex/2ac66123e9a17cce48fa1de3be11d7d68/jelias}, doi = {10.1097/INF.0b013e318199f62d}, interhash = {13539e4da0c4f1842fd34acd2ebe002d}, intrahash = {ac66123e9a17cce48fa1de3be11d7d68}, issn = {0891-3668}, journal = {The Pediatric Infectious Disease Journal}, keywords = {Bacterial C, Carrier Combined, Conjugate Controlled D, Female, Humans, Immunization Immunization, Immunoglobulin Infant, Lipoproteins, Male, Meningococcal Neisseria Outcome, Pneumococcal Programs, Proteins, Randomized Schedule, Secondary, Serogroup Topic, Treatment Trials Vaccination, Vaccines, as meningitidis,}, month = apr, note = {{PMID:} 19325447}, number = {4 Suppl}, pages = {S109--118}, timestamp = {2011-03-11T10:06:04.000+0100}, title = {Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine {(PHiD-CV)} when coadministered with routine childhood vaccines}, url = {http://www.ncbi.nlm.nih.gov/pubmed/19325447}, volume = 28, year = 2009 }